Next Article in Journal
Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
Previous Article in Journal
Enteropathy-Associated T Cell Lymphoma as a Complication of Silent Celiac Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 7
Issue 1
10.4081/hr.2015.5673
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice

by
Monica Carpenedo
1,*,
Silvia Cantoni
2,
Veronica Coccini
1,
Marilena Fedele
1,
Enrica Morra
2 and
Enrico Maria Pogliani
1
1
Hematology and Transplant Unit, A.O. San Gerardo, University of Milan Bicocca, 20126 Monza, MB, Italy.
2
Hematology and Oncology Department, A.O. Ospedale Niguarda Cà Granda, 20162 Milan, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2015, 7(1), 5673; https://doi.org/10.4081/hr.2015.5673
Submission received: 14 October 2014 / Revised: 18 November 2014 / Accepted: 4 December 2014 / Published: 24 February 2015

Abstract

Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). Because of their mechanism of action, long-term administration was envisioned in order to maintain effective thrombopoiesis. We report on 30 romiplostim treated patients: 13/27 responders (48%) achieved stable platelet counts on a mean romiplostim dose of 2.43 μg/kg and were able to stop romiplostim after a mean of 44.3 weeks (range 12-122) on therapy with sustained response maintained at a mean of 26 months (range 12-52). No bleeding events occurred during the observational period. No specific patient’s features nor pattern of early response seemed to predict for sustained response. However, patients achieving safe platelet counts at lower dosages are probably worth a try of therapy tapering and discontinuation. Our observations support feasibility of romiplostim safe suspension in a relevant proportion of ITP patients.
Keywords: immune thrombocytopenia; thrombopoietin receptor agonists; sustained response immune thrombocytopenia; thrombopoietin receptor agonists; sustained response

Share and Cite

MDPI and ACS Style

Carpenedo, M.; Cantoni, S.; Coccini, V.; Fedele, M.; Morra, E.; Pogliani, E.M. Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice. Hematol. Rep. 2015, 7, 5673. https://doi.org/10.4081/hr.2015.5673

AMA Style

Carpenedo M, Cantoni S, Coccini V, Fedele M, Morra E, Pogliani EM. Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice. Hematology Reports. 2015; 7(1):5673. https://doi.org/10.4081/hr.2015.5673

Chicago/Turabian Style

Carpenedo, Monica, Silvia Cantoni, Veronica Coccini, Marilena Fedele, Enrica Morra, and Enrico Maria Pogliani. 2015. "Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice" Hematology Reports 7, no. 1: 5673. https://doi.org/10.4081/hr.2015.5673

Article Metrics

Back to TopTop